Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Inovio Pharmaceuticals Inc

Healthcare US INO

1.07USD
-0.09(7.76%)

Last update at 2026-06-05T20:21:00Z

Day Range

1.061.17
LowHigh

52 Week Range

3.8914.75
LowHigh

Fundamentals

  • Previous Close 1.16
  • Market Cap269.21M
  • Volume3301128
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-118.55737M
  • Revenue TTM0.72M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -177.38824M
  • Diluted EPS TTM-5.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -277.65285M -303.22432M -162.89030M -120.80911M -94.79802M
Minority interest 0.00000M 0.00000M -1.06376M -1.19256M 0.10M
Net income -287.66424M -305.38496M -215.08644M -120.55178M -96.96783M
Selling general administrative 90.19M 53.75M 37.25M 27.20M 29.32M
Selling and marketing expenses - - - - -
Gross profit 10.26M 1.77M 7.41M 4.11M 30.48M
Reconciled depreciation 5.50M 4.73M 4.63M 5.52M 5.00M
Ebit -267.57352M -301.21792M -124.08204M -111.10855M -94.45193M
Ebitda -268.55273M -293.33426M -76.16957M -105.58048M -89.45517M
Depreciation and amortization -0.97921M 7.88M 47.91M 5.53M 5.00M
Non operating income net other -1.24477M 3.27M -72.94258M 1.34M 1.28M
Operating income -267.57352M -301.21792M -124.08204M -111.10855M -94.09114M
Other operating expenses 277.84M 302.99M 131.49M 115.22M 124.57M
Interest expense 1.25M 1.94M 8.70M 7.95M 0.35M
Tax provision - 0.00000M 0.00000M -0.25733M 2.17M
Interest income 4.78M 3.36M 3.31M 2.61M 0.71M
Net interest income 3.53M 1.43M -5.39060M -5.34256M 0.92M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 10.01M 2.16M 52.20M -0.25733M 2.17M
Total revenue 10.26M 1.77M 7.41M 4.11M 30.48M
Total operating expenses 277.84M 302.99M 131.49M 115.22M 124.57M
Cost of revenue - - - 86.12M 95.26M
Total other income expense net -10.07933M -2.00640M -38.80826M -9.70057M -1.62777M
Discontinued operations - - - - -
Net income from continuing ops -277.65285M -303.22432M -162.89030M -120.50911M -96.96802M
Net income applicable to common shares -279.81806M -303.65871M -166.41116M -119.35922M -96.96802M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 172.94M 348.53M 495.94M 539.77M 143.95M
Intangible assets - 2.13M 2.63M 3.15M 3.69M
Earning assets - - - - -
Other current assets 5.41M 50.51M 39.10M 40.46M 2.63M
Total liab 55.60M 126.17M 96.27M 78.63M 138.55M
Total stockholder equity 117.35M 222.36M 399.67M 461.14M 3.44M
Deferred long term liab - 0.03M - - -
Other current liab 18.74M 13.16M 38.35M 37.86M 22.14M
Common stock 0.02M 0.25M 0.22M 0.19M 0.10M
Capital stock 0.02M 0.25M 0.22M 0.19M 0.10M
Retained earnings -1622.96514M -1487.84778M -1209.85552M -906.19681M -739.78566M
Other liab - 0.03M 0.11M 0.21M 9.12M
Good will 0.00000M 10.51M 10.51M 10.51M 10.51M
Other assets 0.00000M 0.68M 1.43M 43.59M 2.67M
Cash 14.31M 46.33M 71.14M 250.73M 22.20M
Cash and equivalents - - - - -
Total current liabilities 42.57M 96.87M 65.74M 41.71M 31.99M
Current deferred revenue - - 0.02M 0.05M 0.12M
Net debt 15.90M -14.25496M -38.12062M -211.67939M 77.31M
Short term debt 19.18M 2.80M 2.60M 2.33M 2.07M
Short long term debt 16.77M - - - -
Short long term debt total 30.21M 32.07M 33.02M 39.05M 99.51M
Other stockholder equity 1740.95M 1710.66M 1609.59M 1367.41M 742.65M
Property plant equipment - 7.73M 17.45M 11.35M 12.77M
Total current assets 153.11M 315.24M 448.44M 471.17M 94.20M
Long term investments 2.78M 2.01M 3.91M 0.43M 6.32M
Net tangible assets - 209.72M 386.53M 447.48M -10.77212M
Short term investments 130.98M 206.67M 330.17M 160.91M 67.34M
Net receivables 2.41M 11.74M 8.03M 19.06M 2.03M
Long term debt - 16.61M 14.96M 18.66M 77.02M
Inventory - - - - -
Accounts payable 4.65M 80.91M 24.76M 1.47M 7.65M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - 1.97M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.66260M -0.69874M -0.28224M -0.25615M 0.47M
Additional paid in capital - - - - -
Common stock total equity - 0.25M 0.22M 0.19M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - -1487.84778M -1209.85552M -906.19681M -739.78566M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.61M 0.68M 1.43M 25.96M 2.67M
Deferred long term asset charges - - - - -
Non current assets total 19.83M 33.29M 47.50M 68.60M 49.75M
Capital lease obligations 13.44M 15.46M 18.06M 20.39M 22.48M
Long term debt total - 16.61M - - 77.02M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 112.56M -174.11348M -93.22565M -8.05707M 44.50M
Change to liabilities 32.59M 26.10M 3.27M -4.63440M -2.25154M
Total cashflows from investing activities 109.59M -175.34448M -58.79575M -9.04500M 42.42M
Net borrowings - - 0.17M 94.13M 97.44M
Total cash from financing activities 81.84M 211.50M 465.28M 105.40M 31.04M
Change to operating activities -6.94575M 16.19M -57.86964M -3.51351M -1.36228M
Net income -279.81806M -303.65871M -167.47491M -120.55178M -96.96783M
Change in cash -24.81442M -179.58434M 228.53M -1.49754M -0.09295M
Begin period cash flow 71.14M 250.73M 22.20M 23.69M 23.79M
End period cash flow 46.33M 71.14M 250.73M 22.20M 23.69M
Total cash from operating activities -216.21542M -215.70853M -177.97905M -97.85014M -73.55016M
Issuance of capital stock 82.96M 209.44M 454.49M 9.09M 29.23M
Depreciation 5.50M 4.73M 4.63M 5.52M 5.00M
Other cashflows from investing activities -2.00000M - 35.95M -8.05707M 44.50M
Dividends paid - - - - -
Change to inventory - 15.55M -55.15362M 0.94M -0.96392M
Change to account receivables -3.70617M 11.03M -17.01547M 2.02M 2.43M
Sale purchase of stock 82.96M 209.44M 456.87M 12.05M 29.23M
Other cashflows from financing activities -1.11461M 2.06M 10.79M 96.31M 1.81M
Change to netincome 30.01M 27.46M 95.91M 17.43M 10.27M
Capital expenditures 0.97M 1.23M 1.52M 0.99M 2.09M
Change receivables -3.70617M 11.03M -17.01547M 2.02M 2.43M
Cash flows other operating 1.87M 18.17M -96.25275M 3.22M 7.89M
Exchange rate changes - - - - -
Cash and cash equivalents changes -24.78886M -179.55421M 228.50M -1.49754M -0.09295M
Change in working capital 19.83M 50.35M -71.07182M -3.54312M 4.71M
Stock based compensation 22.56M 26.34M 15.65M 10.90M 10.65M
Other non cash items 15.72M 0.86M 2.36M 10.09M -0.36079M
Free cash flow -217.18457M -216.93953M -179.49971M -98.83806M -75.63518M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INO
Inovio Pharmaceuticals Inc		 -0.09 7.76% 1.07 - - 309.82 2.20 171.50 -1.0943
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc

660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Key Executives

Name Title Year Born
Dr. Jacqueline E. Shea Ph.D. CEO, Pres & Director 1966
Mr. Peter D. Kies Chief Financial Officer 1963
Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer 1967
Ben Matone Director of Investor Relations NA
Mr. Robert L. Crotty J.D. Gen. Counsel 1974
Ms. Asli Gevgilili Chief HR Officer NA
Mr. E. J. Brandreth MBA Sr. VP of Quality Assurance NA
Dr. Jeffrey Skolnik Sr. VP of Clinical Devel. NA
Mr. Robert J. Juba Jr. Sr. VP of Biological Manufacturing & Clinical Supply Management NA
Mr. Daniel Jordan Sr. VP of Device Manufacturing Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions